Box 1.	Questions addressing the role of CAR T-cells in earlier lines of therapy for myeloma
FAQ 1	What are the 2 currently approved CAR T-Cell therapies for Relapsed/Refractory Myeloma, and what studies and data led to their approval?
FAQ 2	What mitigation strategies can be utilized to try to decrease the risk of severe CRS and neurotoxicity after CAR T-cell therapy for myeloma?
FAQ 3	What other specific risks are seen with CAR T-Cell Therapy besides CRS and Neurotoxicity?
FAQ 4	What considerations will help us choose between one BCMA CAR T-cell product over another?
FAQ 5	Many patients don’t fit the eligibility criteria for the trials used for approval of CAR T-cells. What is the data for CAR T-cell therapy outside of the clinical trial setting?
FAQ 6	What are some bridging strategies for effective cytoreduction to mitigate risks or keep the myeloma under control in penta-refractory patients during product manufacturing?
FAQ 7	With multiple treatment options and modalities targeting BCMA (CAR T-cells, Bispecific T-cell engagers), what are some considerations for sequencing BCMA directed therapies?
FAQ 8	Are there T-cell markers predictive for poor outcome after CAR T-cell therapy, and what are the reasons that CAR T-cells may be more effective earlier in the course of disease?
FAQ 9	What are the studies being done, and what data has been reported from randomized trials to support moving CAR T-cells to 2nd or 3rd line therapy for myeloma?
FAQ 10	What studies are being done, and what data would be needed to move CAR T-cells to frontline therapy of myeloma?
FAQ 11	Will moving CAR T-cells to earlier lines of therapy for myeloma be cost prohibitive, and will the quality of life improvement with CAR T justify a cost difference?
FAQ 12	For patients relapsing after BCMA-directed therapy, what options do we have, and what data do we have for non-BCMA T-cell redirection therapies?